Finance

Permira seeks $4 billion for sale of contract drugmaker Cambrex, FT reports

Published by Global Banking & Finance Review

Posted on September 6, 2025

1 min read

· Last updated: January 22, 2026

Add as preferred source on Google
Founders of The Entertainer toy chain hand over control to workers - Global Banking & Finance Review
Image depicting the founders of The Entertainer, Gary and Catherine Grant, announcing the transition of their toy retailer to employee ownership, emphasizing the significance of this move in the finance sector.
Global Banking & Finance Awards 2026 — Call for Entries

(Reuters) -British private equity firm Permira has put its contract drugmaker Cambrex up for sale, targeting a valuation of as much as $4 billion, the Financial Times reported on Saturday citing

Permira seeks $4 billion for sale of contract drugmaker Cambrex, FT reports

(Reuters) -British private equity firm Permira has put its contract drugmaker Cambrex up for sale, targeting a valuation of as much as $4 billion, the Financial Times reported on Saturday citing people familiar with the matter.

Reuters could not immediately verify the report.

(Reporting by Anusha Shah in Bengaluru; Editing by Aidan Lewis)

Key Takeaways

  • Permira is selling Cambrex, a contract drugmaker.
  • The targeted valuation for Cambrex is $4 billion.
  • The Financial Times reported the potential sale.
  • Reuters has not verified the report.
  • Cambrex is a significant asset for Permira.

Frequently Asked Questions

Who is selling Cambrex?
The British private equity firm Permira is selling its contract drugmaker Cambrex.
What is the targeted valuation for Cambrex?
Permira is targeting a valuation of as much as $4 billion for Cambrex.
Which publication reported on the Cambrex sale?
The Financial Times reported on the sale of Cambrex by Permira.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category